Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung Cancers


Release Date: November 30, 2018
Expiration Date: November 30, 2019
Media: Internet - based

Activity Overview

This online Physicians’ Education Resource, LLC, (PER®) activity, Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung Cancers, is designed to update physicians on data presented at the World Conference on Lung Cancer, which took place September 23-26, 2018, in Toronto, Canada. During this online activity, the program faculty, Karen Reckamp, MD, MS, will review 3 abstracts chosen as the most clinically relevant to facilitate integration of cutting-edge data into practice. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participating

  • Increased knowledge of recent cutting-edge clinical trial results that impact treatment of patients with lung cancer
  • Hear expert perspectives on the clinical context of emerging data from the World Conference on Lung Cancer
  • Identify key ongoing clinical trials for patients with small cell lung cancer, ALK mutation–positive non-small cell lung cancer (NSCLC), and locally advanced stage III NSCLC

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, pulmonologists, and nurses involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer are also invited to participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  • Detail the design, efficacy, and safety readouts of presented completed and ongoing clinical trials evaluating novel treatment strategies in the setting of advanced lung cancer
  • Integrate recent trial safety and efficacy results in the context of evolving treatment paradigms for the treatment of lung cancer
  • Identify planned/ongoing clinical trials intended to address remaining unanswered clinical questions in the field of advanced lung cancer management

Faculty, Staff, and Planners' Disclosures

Faculty

Karen L. Reckamp, MD, MS
Professor
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
 

Disclosures: Grant/Research Support: AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Guardant, Janssen, Loxo Oncology, Seattle Genetics, Takeda, Xcovery, Zeno; Consultant: Boehringer Ingelheim, Euclises, Exelixis, Guardant, Genentech, Loxo, Precision Health, Seattle Genetics, Takeda, Tesaro

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse™ Recaps

1 of 3

The online Physicians’ Education Resource®, LLC (PER), Burst CME™ activity, Cancer Summaries and Commentaries™—Update from Toronto: Advances in the Treatment of Lung Cancers, is designed to update physicians on data presented at the 19th International Association for the Study of Lung Cancer World Conference on Lung Cancer, which took place September 23 to 26, 2018, in Toronto, Ontario, Canada. Karen Reckamp, MD, MS, reviews 3 of the most clinically relevant abstracts with the potential to change practice in the near future.

This first of 3 PER Pulse™ Recaps from this Cancer Summaries and Commentaries™ focuses on emerging data regarding the use of atezolizumab in the first-line treatment of extensive stage small cell lung cancer (ES-SCLC).

Limited progress has been made in the care of ES-SCLC over the past several decades, particularly in the frontline setting, and conventional treatment has relied on carboplatin or cisplatin with etoposide. In the IMPower133 phase III trial, patients with ES-SCLC received carboplatin plus etoposide with either atezolizumab or placebo. The adverse events observed with the addition of atezolizumab to this treatment regimen did not reveal any new safety signals compared with atezolizumab monotherapy. Median overall survival (OS) was significantly increased in the atezolizumab arm at 12.3 months compared with 10.3 months in the placebo arm, and 12-month OS rates were 51.7% with atezolizumab and 38.2% with placebo. Dr Reckamp points out that improving OS for patients with ES-SCLC beyond 12 months represents a significant clinical advance for these patients.1,2 Atezolizumab is now indicated for use as first-line treatment in combination with carboplatin and etoposide for ES-SCLC.3

References

  1. Liu SV, Mansfield AS, Szczesna A, et al. IMpower 133: primary PFS, OS and safety in a PH1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC. Presented at: International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer; September 23-26, 2018; Toronto, Ontario, Canada. Abstract PL02.07. jto.org/article/S1556-0864(18)30971-7/fulltext Accessed November 20, 2018.
  2. Horn L, Mansfield AS, Szczesna A, et al; Impower133 Study Group. First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220-2229. doi: 10.1056/NEJMoa1809064.
  3. Tecentriq (atezolizumab) [package insert]. South San Francisco, CA: Genentech; May 2019.

2 of 3

The online Physicians’ Education Resource®, LLC (PER), Burst CME™ activity, Cancer Summaries and Commentaries—Update from Toronto: Advances in the Treatment of Lung Cancers, is designed to update physicians on data presented at the 19th International Association for the Study of Lung Cancer World Conference on Lung Cancer, which took place September 23 to 26, 2018, in Toronto, Ontario, Canada. Karen Reckamp, MD, MS, reviews 3 of the most clinically relevant abstracts with the potential to change practice in the near future.

This second of 3 PER Pulse™ Recaps from this Cancer Summaries and Commentaries™ focuses on updated results presented on the overall survival (OS) analysis of the PACIFIC trial examining the use of durvalumab to treat stage III non–small cell lung cancer (NSCLC).1

  • The conventional treatment for stage III NSCLC is chemoradiotherapy using platinum doublet chemotherapy and results in median progression-free survival (mPFS) of approximately 8 months.
  • An earlier interim analysis of data from the PACIFIC trial demonstrated a significant improvement in mPFS for patients receiving durvalumab after chemoradiotherapy compared with placebo after chemoradiotherapy.
  • At a median follow-up of 25.2 months, the OS was not reached for the durvalumab group compared with 28.7 months for the placebo group.
  • The updated mPFS reported in this interim analysis was 17.2 months for the durvalumab group compared with 5.6 months for the placebo group.
  • Dr Reckamp points out that occurrence of grade 3/4 pneumonitis was not significantly different for the group receiving durvalumab compared with placebo, an important concern because patients receiving either radiation or immunotherapy alone are at risk of developing pneumonitis.

Reference

  1. Antonia SJ, Villegas A, Daniel D, et al; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350. doi: 10.1056/NEJMoa1809697.

3 of 3

The online Physicians’ Education Resource®, LLC (PER), Burst CME™ activity, Cancer Summaries and Commentaries—Update from Toronto: Advances in the Treatment of Lung Cancers, is designed to update physicians on data presented at the 19th International Association for the Study of Lung Cancer World Conference on Lung Cancer, which took place September 23 to 26, 2018, in Toronto, Ontario, Canada. Karen Reckamp, MD, MS, reviews 3 of the most clinically relevant abstracts with the potential to change practice in the near future.

This third of 3 PER Pulse™ Recaps from this Cancer Summaries and Commentaries™ focuses on results reported for the first interim analysis of the phase III ALTA-1L trial examining the treatment of ALK-positive non–small cell lung cancer (NSCLC) with brigatinib.

Anaplastic lymphoma kinase (ALK) rearrangements are found in 3% to 5% of NSCLC cases. The tyrosine kinase inhibitor brigatinib is indicated for the treatment of metastatic ALK-positive NSCLC after progression on or intolerance of crizotinib. In the ALTA-1L trial, patients with stage IIIb/IV NSCLC receive either brigatinib or crizotinib as first-line treatment or after 1 prior line of therapy excluding ALK inhibitors, and central nervous system metastases were allowed. Median progression-free survival as assessed by central review was not reached with brigatinib and was 9.8 months with crizotinib at a median follow-up time of 11.0 months and 9.3 months, respectively.1

Dr Reckamp points out that this analysis represents a short follow-up time, but brigatinib demonstrated efficacy as a first-line treatment in this analysis. Continued follow-up of this and other randomized phase III trials in advanced NSCLC may advance new first-line treatment options in this patient population.

Reference

  1. Camidge R, Kim HR, Ahn M, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). Presented at: International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer; September 23-26, 2018; Toronto, Ontario, Canada. Abstract PL02.03. jto.org/article/S1556-0864(18)30969-9/abstract Accessed November 20, 2018.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By